The neurodegenerative illness Machado-Joseph illness (MJD), often known as spinocerebellar ataxin-3, impacts neurons of the mind and spinal twine, disrupting management of the motion of muscle groups. Now we have efficiently established the primary transgenic zebrafish (Danio rerio) mannequin of MJD by expressing human ataxin-Three protein containing both 23 glutamines (23Q, wild-type) or 84Q (MJD-causing) inside neurons. Phenotypic characterization of the zebrafish (female and male) revealed that the ataxin-3-84Q zebrafish have decreased survival in contrast with ataxin-3-23Q and develop ataxin-Three neuropathology, ataxin-Three cleavage fragments and motor impairment. Ataxin-3-84Q zebrafish swim shorter distances than ataxin-3-23Q zebrafish as early as 6 days previous, even when expression of the human ataxin-Three protein is proscribed to motor neurons.
This swimming phenotype gives a invaluable readout for drug therapy research. Treating the EGFP-ataxin-3-84Q zebrafish with the calpain inhibitor compound calpeptin decreased ranges of ataxin-Three cleavage fragments, but in addition eliminated all human ataxin-Three protein (confirmed by ELISA) and prevented the early MJD zebrafish motor phenotype. We recognized that this clearance of ataxin-Three protein by calpeptin therapy resulted from a rise in autophagic flux (indicated by decreased p62 ranges and elevated LC3II). Cotreatment with the autophagy inhibitor chloroquine blocked the lower in human ataxin-Three ranges and the improved motion produced by calpeptin therapy. This examine demonstrates that this primary transgenic zebrafish mannequin of MJD is a invaluable instrument for testing potential therapies for MJD. Calpeptin therapy is protecting on this mannequin of MJD and removing of human ataxin-Three by means of macro-autophagy performs an essential function on this useful impact.
SIGNIFICANCE STATEMENT Now we have established the primary transgenic zebrafish mannequin of the neurodegenerative illness MJD, and recognized related illness phenotypes, together with impaired motion from an early age, which can be utilized in fast drug testing research. Now we have discovered that treating the MJD zebrafish with the calpain inhibitor compound calpeptin produces full removing of human ataxin-Three protein, as a consequence of induction of the autophagy high quality management pathway. This improves the motion of the MJD zebrafish. Artificially blocking the autophagy pathway prevents the removing of human ataxin-Three and improved motion produced by calpeptin therapy. These findings point out that induction of autophagy, and removing of ataxin-Three protein, performs an essential function within the protecting results of calpain inhibition for the therapy of MJD.
Disruption of the ATXN1-CIC complicated causes a spectrum of neurobehavioral phenotypes in mice and people.
Acquire-of-function mutations in some genes underlie neurodegenerative circumstances, whereas loss-of-function mutations in the identical genes have distinct phenotypes. This seems to be the case with the protein ataxin 1 (ATXN1), which varieties a transcriptional repressor complicated with capicua (CIC). Acquire of perform of the complicated results in neurodegeneration, however ATXN1-CIC can be important for survival. We got down to perceive the features of the ATXN1-CIC complicated within the creating forebrain and located that dropping this complicated ends in hyperactivity, impaired studying and reminiscence, and irregular maturation and upkeep of upper-layer cortical neurons.
We additionally discovered that CIC exercise within the hypothalamus and medial amygdala modulates social interactions. Knowledgeable by these neurobehavioral options in mouse mutants, we recognized 5 people with de novo heterozygous truncating mutations in CIC who share related medical options, together with mental incapacity, consideration deficit/hyperactivity dysfunction (ADHD), and autism spectrum dysfunction. Our examine demonstrates that lack of ATXN1-CIC complexes causes a spectrum of neurobehavioral phenotypes. The Chk1 protein is crucial for genome integrity upkeep and cell survival in eukaryotic cells. After extended replication stress, Chk1 may be focused for proteasomal degradation to terminate checkpoint signaling after DNA restore finishes. To make sure correct activation of DNA injury checkpoint and DNA restore signaling, a steady-state degree of Chk1 must be retained underneath physiological circumstances.
Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy.
Epigallocatechin-3-gallate and associated phenol compounds redirect the amyloidogenic aggregation pathway of ataxin-Three in the direction of non-toxic aggregates and stop toxicity in neural cells and Caenorhabditis elegans animal mannequin.
The protein ataxin-3 (ATX3) triggers an amyloid-related neurodegenerative illness when its polyglutamine stretch is expanded past a important threshold. We previously demonstrated that the polyphenol epigallocatechin-3-gallate (EGCG) may redirect amyloid aggregation of a full-length, expanded ATX3 (ATX3-Q55) in the direction of non-toxic, soluble, SDS-resistant aggregates.
Right here, we have now characterised different associated phenol compounds, though smaller in measurement, i.e. (-)-epigallocatechin gallate (EGC), and gallic acid (GA). We analysed the aggregation sample of ATX3-Q55 and of the N-terminal globular Josephin area (JD) by assessing the time course of the soluble protein, as effectively its structural options by FTIR and AFM, within the presence and the absence of the talked about compounds. All of them redirected the aggregation sample in the direction of soluble, SDS-resistant aggregates. Additionally they prevented the looks of ordered side-chain hydrogen bonding in ATX3-Q55, which is the hallmark of polyQ-related amyloids. Molecular docking analyses on the JD highlighted three interacting areas, together with the central, aggregation-prone one. All three compounds sure to every of them, though with completely different patterns.
Ataxin 7 Antibody |
|||
| MBS858677-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Ataxin 7 Antibody |
|||
| MBS858677-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Ataxin 7 (ATXN7) Antibody |
|||
| 20-abx121290 | Abbexa |
|
|
Ataxin 7 (ATXN7) Antibody |
|||
| 20-abx148459 | Abbexa |
|
|
Ataxin 7 (ATXN7) Antibody |
|||
| abx038315-100ug | Abbexa | 100 ug | EUR 469.2 |
Ataxin 7 (ATXN7) Antibody |
|||
| abx029159-400ul | Abbexa | 400 ul | EUR 627.6 |
Ataxin 7 (ATXN7) Antibody |
|||
| abx029159-80l | Abbexa | 80 µl | EUR 343.2 |
Ataxin 7 (ATXN7) Antibody |
|||
| 20-abx338870 | Abbexa |
|
|
Ataxin 7 (ATXN7) Antibody |
|||
| abx038315-1mg | Abbexa | 1 mg | EUR 337.5 |
Ataxin 7 (ATXN7) Antibody |
|||
| abx029159-400l | Abbexa | 400 µl | EUR 518.75 |
Ataxin 7 (ATXN7) Antibody |
|||
| abx338870-100l | Abbexa | 100 µl | EUR 250 |
Ataxin 7 (ATXN7) Antibody |
|||
| abx338870-50l | Abbexa | 50 µl | EUR 162.5 |
Ataxin 7 Polyclonal Antibody |
|||
| MBS9234025-01mL | MyBiosource | 0.1mL | EUR 415 |
Ataxin 7 Polyclonal Antibody |
|||
| MBS9234025-5x01mL | MyBiosource | 5x0.1mL | EUR 1841 |
Ataxin 7 (ATXN7) Antibody (HRP) |
|||
| 20-abx334734 | Abbexa |
|
|
Ataxin 7 (ATXN7) Antibody (HRP) |
|||
| abx334734-100g | Abbexa | 100 µg | EUR 362.5 |
Ataxin 7 (ATXN7) Antibody (HRP) |
|||
| abx334734-20g | Abbexa | 20 µg | EUR 162.5 |
Ataxin 7 (ATXN7) Antibody (HRP) |
|||
| abx334734-50g | Abbexa | 50 µg | EUR 250 |
Ataxin 7 (ATXN7) Antibody (FITC) |
|||
| 20-abx334735 | Abbexa |
|
|
Ataxin 7 (ATXN7) Antibody (FITC) |
|||
| abx334735-100g | Abbexa | 100 µg | EUR 362.5 |
Ataxin 7 (ATXN7) Antibody (FITC) |
|||
| abx334735-20g | Abbexa | 20 µg | EUR 162.5 |
Ataxin 7 (ATXN7) Antibody (FITC) |
|||
| abx334735-50g | Abbexa | 50 µg | EUR 250 |
Ataxin 7 (ATXN7) Antibody (Biotin) |
|||
| 20-abx334736 | Abbexa |
|
|
Ataxin 7 (ATXN7) Antibody (Biotin) |
|||
| abx334736-100g | Abbexa | 100 µg | EUR 362.5 |
Ataxin 7 (ATXN7) Antibody (Biotin) |
|||
| abx334736-20g | Abbexa | 20 µg | EUR 162.5 |
Ataxin 7 (ATXN7) Antibody (Biotin) |
|||
| abx334736-50g | Abbexa | 50 µg | EUR 250 |
Ataxin 3 antibody |
|||
| 22437 | SAB | 100ul | EUR 479 |
Ataxin 3 antibody |
|||
| 22437-100ul | SAB | 100ul | EUR 468 |
Ataxin 1 Antibody |
|||
| E11-0771B | EnoGene | 100μg | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Ataxin 1 Antibody |
|||
| E18-6347-1 | EnoGene | 50μg/50μl | EUR 145 |
|
Description: Available in various conjugation types. |
|||
Ataxin 1 Antibody |
|||
| E18-6347-2 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Ataxin 3 Antibody |
|||
| DF6375 | Affbiotech | 200ul | EUR 420 |
Ataxin 3 Antibody |
|||
| DF6375-100ul | Affinity Biosciences | 100ul | EUR 280 |
Ataxin 3 Antibody |
|||
| DF6375-200ul | Affinity Biosciences | 200ul | EUR 350 |
Ataxin 2 Antibody |
|||
| E38PA2046 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Ataxin 10 Antibody |
|||
| E38PA2595 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Ataxin 3 Antibody |
|||
| E300595 | EnoGene | 100ug/200ul | EUR 275 |
|
Description: Available in various conjugation types. |
|||
Ataxin 3 antibody |
|||
| 70R-13630 | Fitzgerald | 100 ul | EUR 548 |
|
Description: Affinity purified Rabbit polyclonal Ataxin 3 antibody |
|||
Ataxin 10 antibody |
|||
| 70R-50914 | Fitzgerald | 100 ul | EUR 242 |
|
Description: Purified Polyclonal Ataxin 10 antibody |
|||
Ataxin 2 antibody |
|||
| 70R-50365 | Fitzgerald | 100 ul | EUR 242 |
|
Description: Purified Polyclonal Ataxin 2 antibody |
|||
Ataxin 1 Antibody |
|||
| AF6347 | Affbiotech | 200ul | EUR 420 |
Ataxin 1 Antibody |
|||
| AF6347-100ul | Affinity Biosciences | 100ul | EUR 280 |
Ataxin 1 Antibody |
|||
| AF6347-200ul | Affinity Biosciences | 200ul | EUR 350 |
Ataxin 1 Antibody |
|||
| ABF6347 | Nova Lifetech | 100ug | EUR 325 |
Ataxin 3 antibody |
|||
| MBS9404933-01mL | MyBiosource | 0.1mL | EUR 420 |
Ataxin 3 antibody |
|||
| MBS9404933-5x01mL | MyBiosource | 5x0.1mL | EUR 1740 |
Ataxin 1 Antibody |
|||
| MBS801582-01mg | MyBiosource | 0.1mg | EUR 435 |
Ataxin 1 Antibody |
|||
| MBS801582-5x01mg | MyBiosource | 5x0.1mg | EUR 1700 |
Ataxin 1 Antibody |
|||
| MBS804474-01mg | MyBiosource | 0.1mg | EUR 435 |
Ataxin 1 Antibody |
|||
| MBS804474-5x01mg | MyBiosource | 5x0.1mg | EUR 1700 |
Ataxin 10 Antibody |
|||
| MBS9208403-01mL | MyBiosource | 0.1mL | EUR 415 |
Ataxin 10 Antibody |
|||
| MBS9208403-5x01mL | MyBiosource | 5x0.1mL | EUR 1841 |
Ataxin 2 Antibody |
|||
| MBS9212932-01mL | MyBiosource | 0.1mL | EUR 415 |
Ataxin 2 Antibody |
|||
| MBS9212932-5x01mL | MyBiosource | 5x0.1mL | EUR 1841 |
Ataxin 2 Antibody |
|||
| MBS8581030-01mL | MyBiosource | 0.1mL | EUR 305 |
Ataxin 2 Antibody |
|||
| MBS8581030-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
Ataxin 2 Antibody |
|||
| MBS8581030-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
Ataxin 2 Antibody |
|||
| MBS8581030-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
Ataxin 2 Antibody |
|||
| MBS8581030-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
Ataxin 10 Antibody |
|||
| MBS8581427-01mL | MyBiosource | 0.1mL | EUR 305 |
Ataxin 10 Antibody |
|||
| MBS8581427-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
Ataxin 10 Antibody |
|||
| MBS8581427-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
Ataxin 10 Antibody |
|||
| MBS8581427-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
Ataxin 10 Antibody |
|||
| MBS8581427-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
Ataxin 1 Antibody |
|||
| MBS8509598-01mg | MyBiosource | 0.1mg | EUR 305 |
Ataxin 1 Antibody |
|||
| MBS8509598-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
Ataxin 1 Antibody |
|||
| MBS8509598-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
Ataxin 1 Antibody |
|||
| MBS8509598-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
Ataxin 1 Antibody |
|||
| MBS8509598-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
Ataxin 1 Antibody |
|||
| MBS8512374-005mg | MyBiosource | 0.05mg | EUR 235 |
Ataxin 1 Antibody |
|||
| MBS8512374-01mg | MyBiosource | 0.1mg | EUR 305 |
Ataxin 1 Antibody |
|||
| MBS8512374-01mLAF405M | MyBiosource | 0.1mL(AF405M) | EUR 465 |
Ataxin 1 Antibody |
|||
| MBS8512374-01mLAF546 | MyBiosource | 0.1mL(AF546) | EUR 465 |
Ataxin 1 Antibody |
|||
| MBS8512374-01mLAF750 | MyBiosource | 0.1mL(AF750) | EUR 465 |
Ataxin 3 Antibody |
|||
| MBS853397-01mg | MyBiosource | 0.1mg | EUR 345 |
Ataxin 3 Antibody |
|||
| MBS853397-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Ataxin 3 Antibody |
|||
| MBS853397-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Ataxin 3 Antibody |
|||
| MBS853397-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Ataxin 3 Antibody |
|||
| MBS853397-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Ataxin 2 Antibody |
|||
| MBS5314984-01mL | MyBiosource | 0.1mL | EUR 470 |
Ataxin 2 Antibody |
|||
| MBS5314984-5x01mL | MyBiosource | 5x0.1mL | EUR 1955 |
Ataxin 10 Antibody |
|||
| MBS5315532-01mL | MyBiosource | 0.1mL | EUR 470 |
Ataxin 10 Antibody |
|||
| MBS5315532-5x01mL | MyBiosource | 5x0.1mL | EUR 1955 |
Ataxin 3 Antibody |
|||
| MBS5312481-01mL | MyBiosource | 0.1mL | EUR 1065 |
Ataxin 3 Antibody |
|||
| MBS5312481-5x01mL | MyBiosource | 5x0.1mL | EUR 4640 |
Ataxin 1 Antibody |
|||
| MBS9601916-01mL | MyBiosource | 0.1mL | EUR 260 |
Ataxin 1 Antibody |
|||
| MBS9601916-02mL | MyBiosource | 0.2mL | EUR 305 |
Ataxin 1 Antibody |
|||
| MBS9601916-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
Ataxin 1 Antibody |
|||
| MBS9503754-005mL | MyBiosource | 0.05mL | EUR 285 |
Ataxin 1 Antibody |
|||
| MBS9503754-01mL | MyBiosource | 0.1mL | EUR 385 |
Ataxin 1 Antibody |
|||
| MBS9503754-5x01mL | MyBiosource | 5x0.1mL | EUR 1590 |
Ataxin 7 Like 1 (ATXN7L1) Antibody |
|||
| 20-abx325156 | Abbexa |
|
|
Ataxin 7 Like 1 (ATXN7L1) Antibody |
|||
| abx325156-100g | Abbexa | 100 µg | EUR 250 |
Ataxin 7 Like 1 (ATXN7L1) Antibody |
|||
| abx325156-50g | Abbexa | 50 µg | EUR 187.5 |
Ataxin-1 Antibody |
|||
| E90506 | EnoGene | 100μg | EUR 255 |
|
Description: Available in various conjugation types. |
|||
Ataxin-2 Antibody |
|||
| R31210 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: Ataxin-2, the protein encoded by the ATXN2 gene, contains a polyglutamine tract, long expansions (greater than 33 repeats) of which result in spinocerebellar ataxia-2 (SCA2), an autosomal dominant form of olivopontocerebellar atrophy. The gene for spinocerebellar ataxia type 2(SCA2) has been mapped to 12q24.1. Ataxin-2 associates with L- and T-plastin and overexpression leads to accumulation of T-plastin in mammalian cells. |
|||
Ataxin-1 Antibody |
|||
| MBS8503880-01mg | MyBiosource | 0.1mg | EUR 325 |
Ataxin-1 Antibody |
|||
| MBS8503880-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Ataxin-1 Antibody |
|||
| MBS8503880-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Ataxin-1 Antibody |
|||
| MBS8503880-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Ataxin-1 Antibody |
|||
| MBS8503880-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Ataxin-1 Antibody |
|||
| B0771-100ul | Assay Biotech | 100μl | EUR 217 |
|
Description: Ataxin-1 Rabbit Polyclonal Antibody |
|||
Ataxin-1 Antibody |
|||
| B0771-50ul | Assay Biotech | 50μl | EUR 143.5 |
|
Description: Ataxin-1 Rabbit Polyclonal Antibody |
|||
Ataxin-2 Antibody |
|||
| C14578-100ul | Assay Biotech | 100μl | EUR 217 |
|
Description: Ataxin-2 Rabbit Polyclonal Antibody |
|||
Ataxin-2 Antibody |
|||
| C14578-50ul | Assay Biotech | 50μl | EUR 143.5 |
|
Description: Ataxin-2 Rabbit Polyclonal Antibody |
|||
Ataxin-2L Antibody |
|||
| C14580-100ul | Assay Biotech | 100μl | EUR 217 |
|
Description: Ataxin-2L Rabbit Polyclonal Antibody |
|||
Ataxin-2L Antibody |
|||
| C14580-50ul | Assay Biotech | 50μl | EUR 143.5 |
|
Description: Ataxin-2L Rabbit Polyclonal Antibody |
|||
Ataxin-7L1 Antibody |
|||
| C14583-100ul | Assay Biotech | 100μl | EUR 217 |
|
Description: Ataxin-7L1 Rabbit Polyclonal Antibody |
|||
Ataxin-7L1 Antibody |
|||
| C14583-50ul | Assay Biotech | 50μl | EUR 143.5 |
|
Description: Ataxin-7L1 Rabbit Polyclonal Antibody |
|||
Ataxin-7-Like Protein 2 (ATXN7L2) Antibody |
|||
| 20-abx121022 | Abbexa |
|
|
Ataxin-7-Like Protein 3 (ATXN7L3) Antibody |
|||
| 20-abx121023 | Abbexa |
|
|
Ataxin-7-Like Protein 1 (ATXN7L1) Antibody |
|||
| 20-abx121291 | Abbexa |
|
|
Ataxin-7-Like Protein 1 (ATXN7L1) Antibody |
|||
| 20-abx148460 | Abbexa |
|
|
Ataxin-7-Like Protein 3 (ATXN7L3) Antibody |
|||
| abx037189-100ug | Abbexa | 100 ug | EUR 469.2 |
Ataxin-7-Like Protein 2 (ATXN7L2) Antibody |
|||
| abx219541-100ug | Abbexa | 100 ug | EUR 526.8 |
Ataxin-7-Like Protein 3 (ATXN7L3) Antibody |
|||
| 20-abx301379 | Abbexa |
|
|
Ataxin-7-Like Protein 1 (ATXN7L1) Antibody |
|||
| 20-abx301749 | Abbexa |
|
|
Ataxin-7-Like Protein 1 (ATXN7L1) Antibody |
|||
| abx301749-100g | Abbexa | 100 µg | EUR 362.5 |
Ataxin-7-Like Protein 1 (ATXN7L1) Antibody |
|||
| abx301749-20g | Abbexa | 20 µg | EUR 162.5 |
Ataxin-7-Like Protein 1 (ATXN7L1) Antibody |
|||
| abx301749-50g | Abbexa | 50 µg | EUR 250 |
Ataxin-7-Like Protein 3 (ATXN7L3) Antibody |
|||
| abx037189-96tests | Abbexa | 96 tests | EUR 337.5 |
Ataxin-7-Like Protein 3 (ATXN7L3) Antibody |
|||
| abx301379-100g | Abbexa | 100 µg | EUR 362.5 |
Ataxin-7-Like Protein 3 (ATXN7L3) Antibody |
|||
| abx301379-20g | Abbexa | 20 µg | EUR 162.5 |
Ataxin-7-Like Protein 3 (ATXN7L3) Antibody |
|||
| abx301379-50g | Abbexa | 50 µg | EUR 250 |
Rabbit Polyclonal antibody to Ataxin 3 (ataxin 3) |
|||
| TA308320 | Origene Technologies GmbH | 100 µl | Ask for price |
Ataxin 1 Antibody: HRP |
|||
| MBS801879-01mg | MyBiosource | 0.1mg | EUR 475 |
Ataxin 1 Antibody: HRP |
|||
| MBS801879-5x01mg | MyBiosource | 5x0.1mg | EUR 1885 |
Ataxin 1 Antibody: RPE |
|||
| MBS802293-01mg | MyBiosource | 0.1mg | EUR 485 |
Ataxin 1 Antibody: RPE |
|||
| MBS802293-5x01mg | MyBiosource | 5x0.1mg | EUR 1925 |
Ataxin 1 Antibody: RPE |
|||
| MBS802630-01mg | MyBiosource | 0.1mg | EUR 485 |
Ataxin 1 Antibody: RPE |
|||
| MBS802630-5x01mg | MyBiosource | 5x0.1mg | EUR 1925 |
Ataxin 1 Antibody: HRP |
|||
| MBS803533-01mg | MyBiosource | 0.1mg | EUR 475 |
Ataxin 1 Antibody: HRP |
|||
| MBS803533-5x01mg | MyBiosource | 5x0.1mg | EUR 1885 |
anti- Ataxin 2 antibody |
|||
| FNab00657 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against Ataxin 2 |
|||
Ataxin 1 Antibody: FITC |
|||
| MBS801486-01mg | MyBiosource | 0.1mg | EUR 480 |
Ataxin 1 Antibody: FITC |
|||
| MBS801486-5x01mg | MyBiosource | 5x0.1mg | EUR 1905 |
Ataxin 1 Antibody: FITC |
|||
| MBS804612-01mg | MyBiosource | 0.1mg | EUR 480 |
Ataxin 1 Antibody: FITC |
|||
| MBS804612-5x01mg | MyBiosource | 5x0.1mg | EUR 1905 |
Ataxin 7 Like 3 (ATXN7L3) Antibody (HRP) |
|||
| 20-abx306773 | Abbexa |
|
|
Ataxin 7 Like 1 (ATXN7L1) Antibody (HRP) |
|||
| 20-abx312252 | Abbexa |
|
|
Ataxin 7 Like 3 (ATXN7L3) Antibody (HRP) |
|||
| abx306773-100g | Abbexa | 100 µg | EUR 362.5 |
Ataxin 7 Like 3 (ATXN7L3) Antibody (HRP) |
|||
| abx306773-20g | Abbexa | 20 µg | EUR 162.5 |
Ataxin 7 Like 3 (ATXN7L3) Antibody (HRP) |
|||
| abx306773-50g | Abbexa | 50 µg | EUR 250 |
Ataxin 7 Like 1 (ATXN7L1) Antibody (HRP) |
|||
| abx312252-100g | Abbexa | 100 µg | EUR 362.5 |
Ataxin 7 Like 1 (ATXN7L1) Antibody (HRP) |
|||
| abx312252-20g | Abbexa | 20 µg | EUR 162.5 |
Ataxin 7 Like 1 (ATXN7L1) Antibody (HRP) |
|||
| abx312252-50g | Abbexa | 50 µg | EUR 250 |
Ataxin 3 Antibody / ATXN3 |
|||
| F55027-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
|
Description: ATXN3 was known as spinocerebellar ataxia-3, is an autosomal dominant neurologic disorder. The protein contains (CAG)n repeats in the coding region, and the expansion of these repeats from the normal 13-36 to 68-79 is one cause of Machado-Joseph disease. There is a negative correlation between the age of onset and CAG repeat numbers. |
|||
Ataxin 3 Antibody / ATXN3 |
|||
| F55027-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 322.15 |
|
Description: ATXN3 was known as spinocerebellar ataxia-3, is an autosomal dominant neurologic disorder. The protein contains (CAG)n repeats in the coding region, and the expansion of these repeats from the normal 13-36 to 68-79 is one cause of Machado-Joseph disease. There is a negative correlation between the age of onset and CAG repeat numbers. |
|||
Ataxin 3 Antibody / ATXN3 |
|||
| R32137 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: ATXN3 (Ataxin 3), also known as AT3, MJD GENE, MJD1, SCA3 GENE, ATX3, JOS, Spinocerebellar ataxia-3, Machado-Joseph disease protein 1, is a protein that in humans is encoded by the ATXN3 gene. ATXN3 ranges in size from 360 to 374 amino acids. Using Northern blot analysis showed that ATXN3 mRNA was ubiquitously expressed in human tissues. They detected at least 4 ATXN3 transcripts of 1.4, 1.8, 4.5, and 7.5 kb and suggested that the different mRNA species probably result from differential splicing and polyadenylation. Machado-Joseph disease, also known as spinocerebellar ataxia-3, is an autosomal dominant neurologic disorder. The protein encoded by the ATXN3 gene contains (CAG)n repeats in the coding region, and the expansion of these repeats from the normal 13-36 to 68-79 is the cause of Machado-Joseph disease. There is an inverse correlation between the age of onset and CAG repeat numbers. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. Ataxin-3 interacted with 2 human homologs of the yeast DNA repair protein RAD23, HHR23A (RAD23A) and HHR23B (RAD23B). Both normal and mutant ataxin-3 proteins interacted with the ubiquitin-like domain at the N terminus of the HHR23 proteins, which is a motif important for nucleotide excision repair. However, in HEK 293 cells, HHR23A was recruited to intranuclear inclusions formed by the mutant ataxin-3 through its interaction with ataxin-3. |
|||
Ataxin 1 Antibody / ATXN1 |
|||
| R32138 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: Ataxin-1 is a protein that in humans is encoded by the ATXN1 gene. The ATXN1 gene had been mapped to 6p23 by in situ hybridization. Ataxin-1 (ATXN1), a causative factor for spinocerebellar ataxia type 1 (SCA1), and the related Brother of ATXN1 (BOAT1) are human proteins involved in transcriptional repression. ATXN1 and BOAT1 might participate in several Notch-controlled developmental and pathological processes. |
|||
Ataxin 1 Antibody: PerCP |
|||
| MBS800951-01mg | MyBiosource | 0.1mg | EUR 490 |
Ataxin 1 Antibody: PerCP |
|||
| MBS800951-5x01mg | MyBiosource | 5x0.1mg | EUR 1935 |
Ataxin 1 Antibody: PerCP |
|||
| MBS803830-01mg | MyBiosource | 0.1mg | EUR 490 |
Ataxin 1 Antibody: PerCP |
|||
| MBS803830-5x01mg | MyBiosource | 5x0.1mg | EUR 1935 |
Ataxin 1 Antibody / ATXN1 |
|||
| RQ7132 | NSJ Bioreagents | 100ug | EUR 300.3 |
|
Description: Ataxin-1 is a protein that in humans is encoded by the ATXN1 gene. It is a causative factor for spinocerebellar ataxia type 1 (SCA1), and the related Brother of ATXN1 (BOAT1), are human proteins involved in transcriptional repression. ATXN1 and BOAT1 might participate in several Notch-controlled developmental and pathological processes. |
|||
Ataxin 7 Like 3 (ATXN7L3) Antibody (FITC) |
|||
| 20-abx306774 | Abbexa |
|
|
This would possibly account for his or her functionality to stop amyloidogenesis. Saturation switch distinction NMR experiments additionally confirmed EGCG and EGC binding to monomeric JD. ATX3-Q55 pre-incubation with any of the three compounds prevented its calcium-influx-mediated cytotoxicity in the direction of neural cells. Lastly, all of the phenols considerably diminished toxicity in a transgenic Caenorhabditis elegans pressure expressing an expanded ATX3. General, our outcomes present that the three polyphenols act in a considerably related method. GA, nonetheless, may be extra appropriate for antiamyloid therapies as a consequence of its less complicated construction and better chemical stability.